منابع مشابه
Antibodies to watch in 2013
The transitions of antibody therapeutics to late-stage clinical development, regulatory review and the market are proceeding at a rapid pace in 2013. Since late 2012, two monoclonal antibody (mAb) therapeutics (itolizumab, trastuzumab emtansine) received their first approvals, first marketing applications for three mAbs (vedolizumab, ramucirumab, obinutuzumab) were submitted to regulatory agenc...
متن کاملWhich are the antibodies to watch in 2013?
The start of the new year signals that it is time for mAbs' annual review of the therapeutic monoclonal antibodies (mAbs) in active Phase 2/3 or Phase 3 clinical studies. The entire clinical pipeline currently includes ~350 mAbs, but most of these are in early development. As of the beginning of 2013, our "Antibodies to watch" list includes 28 single mAbs and one mAb mixture that are undergoing...
متن کاملAntibodies to watch in 2017
Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies, which is expected to drive a trend toward first marketing approvals of at least 6-9 mAbs per year in the near-term. In the United States (US), a total of 6 and 9 mAbs were granted first approvals during 2014 and 2015, respectively; all these products are also approv...
متن کاملAntibodies to watch in 2018
The pace of antibody therapeutics development accelerated in 2017, and this faster pace is projected to continue through 2018. Notably, the annual number of antibody therapeutics granted a first approval in either the European Union (EU) or United States (US) reached double-digits (total of 10) for the first time in 2017. The 10 antibodies granted approvals are: brodalumab, dupilumab, sarilumab...
متن کاملJournal Watch Non-HLA antibodies
The clinical impact of non-HLA specific antibodies either alone or in concert with donor HLA specific antibodies (DSA) has been an intense area of research in kidney transplantation and more recently in thoracic transplantation as well. These non-HLA antigens include receptors expressed by the vascular endothelium such as the G protein coupled receptors (GPCRs), Major Histocompatibility Complex...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: mAbs
سال: 2013
ISSN: 1942-0862,1942-0870
DOI: 10.4161/mabs.24990